(B)
	Disease score				t-test for EAE vs. EAE + D
	Mean	SE	95% C.I.		t = 2.40, do = 74, p = 0.0188
EAE	1.670	0.197	1.241	2.100
EAE + D	1.000	0.197	0.570	1.430

The drug administered on days 9 and 10 post-immunization (20 mg/kg) reduced disease severity in both Relapsing-Remitting (RR) (A) and Chronic (CH) (B) EAE mice. Figures 1A,B have the disease scores. Each disease score is the average obtained from five mice/group, in blue for EAE mice and in red for EAE + D mice. Figure 1C shows all disease scores collected from seven experiments at distinct times, together with an estimated line for the disease scores of EAE (blue) and EAE + D (red) mice.

In (A), n represents the number of disease scores. Among the 44 disease scores per group, EAE mice had twenty-five over 1.5, whereas EAE + D mice had only seven over 1.5. (A) has mean disease scores (± SEM) during early (11–14 d.p.i.), mid phase (15–18 d.p.i.), and at the end of disease course (19–32 d.p.i.) with statistically significant differences in EAE vs. EAE + D mice over the course of the entire disease. The cumulative disease score (from all the disease scores) shows also an overall decrease in disease severity of about 50% in EAE+D mice. (B) displays the statistical analysis with a linear regression model and statistically significant differences between EAE and EAE + D mice (Mean = 1,670 and 1,000, respectively; p = 0.0188). n indicates the number of disease scores. Disease score is the average obtained from five mice/group.

^**p < 0.05.